Key Takeaways
- Quality: Intuitive Surgical scores 95/100 on a 33.6% operating margin, $2.6 billion of trailing free cash flow and a current ratio of 4.96, with more cash than debt.
- Growth: revenue grew 18.5% over the trailing twelve months, in line with a 17.4% five-year CAGR, while earnings rose 26.5% – a Rule of 40 reading of about 42 and a Growth score of 64/100.
- Opportunity: despite trading in the lower end of its two-year range, a 46.12 P/E and 1.8% free-cash-flow yield hold Opportunity to 27/100 – below the model’s 30 floor for a Buy, so a 62/100 Recommendation Score yields a Hold.
Intuitive Surgical, maker of the da Vinci robotic surgery system, closed at $401.24, about 33% below its two-year high of $595.55. The business behind the share price is still growing quickly – revenue up 18.5% over the trailing twelve months to $11.0 billion, with a 33.6% operating margin – and it earns a near-perfect Quality score of 95/100. This Intuitive Surgical stock analysis, based on Yahoo Finance data as of October 2, 2026, explains why the scoring model nonetheless rates the stock a Hold: at 46.12 times earnings, the valuation leaves little margin for error.
What Is Happening With the Stock Price
At $401.24, the shares sit in the lower end of their two-year range of $337.50 to $595.55, about 19% above the low. According to published reports, the decline has been driven by slower U.S. procedure growth and new competition, with rival robotic systems from Medtronic (Hugo) and Johnson & Johnson (Ottava) gaining regulatory clearances in soft-tissue surgery. The business itself has kept growing: in the second quarter, Intuitive reported revenue of $2.89 billion, up 19%, worldwide procedures up about 16% and 468 da Vinci systems placed. U.S. da Vinci procedures grew a slower 12%, however, and management guided to full-year procedure growth of roughly 13.5% to 15.5%.
Quality: Is This a Financially Sound Business?
Quality scores 95/100, and this Intuitive Surgical stock analysis finds little to criticize. Gross margin is 66.7%, operating margin 33.6% and net profit margin 28.4%, earned from an installed base the company put at 11,710 da Vinci systems at the end of June. Free cash flow was $2.6 billion over the trailing twelve months, about 83% of the roughly $3.1 billion of net income implied by the margin – solid conversion, if below one-for-one.
The balance sheet is very strong. The current ratio is 4.96 and the quick ratio 3.64; debt-to-equity is not reported in the data, and an enterprise value below the market capitalization implies more cash than debt. Intuitive reported $8.63 billion of cash and investments at June 30, 2026. Return on equity of 17.4% and return on assets of 10.5% are good rather than exceptional, partly because so much of the balance sheet is held in cash and investments.
Growth: Does This Company Have Real Upside?
Growth scores 64/100. Revenue rose 18.5% over the trailing twelve months, closely matching the 17.4% five-year CAGR, and earnings grew faster at 26.5%. Combining blended revenue growth with a 23.7% free-cash-flow margin gives a Rule of 40 reading of about 42, just above the benchmark. The score is held back by the model’s high bar for revenue momentum and by an EV/Revenue multiple of 12.56, which means a good deal of future growth is already priced in. The longer-term question is whether new competitors and slower U.S. procedure growth erode a pace the company has sustained for five years.
Opportunity: Is Now a Good Time to Enter?
Opportunity scores 27/100, and this is where the signal is decided. A P/E of 46.12 equals an earnings yield of only about 2.2%, EV/EBITDA is 33.14, the free-cash-flow yield is 1.8% and price-to-book is 7.82. Even against 26.5% earnings growth, the P/E-to-growth ratio is about 1.7. The model does give credit for the shares trading in the lower end of their two-year range – with Quality this high, it treats the pullback as a potential contrarian setup rather than a value trap – but that cannot offset the rich multiples. The Recommendation Score of 62/100 clears the model’s Buy threshold of 60, yet a Buy also requires Opportunity of at least 30/100, so Intuitive Surgical lands at Hold.
Intuitive Surgical Stock Analysis: The Bottom Line
This Intuitive Surgical stock analysis ends with a model signal of Hold and a Recommendation Score of 62/100, combining Quality 95/100, Growth 64/100 and Opportunity 27/100. The bull case: a large and growing installed base, 18.5% revenue growth, 26.5% earnings growth, a 33.6% operating margin, a cash-rich balance sheet and a share price a third below its two-year high. The bear case: a P/E of 46.12 and a 1.8% free-cash-flow yield that already assume years of strong growth, rising competition from Medtronic and Johnson & Johnson, softer U.S. procedure growth, and tariffs that the company estimates will cost about 1.0% of revenue in gross margin this year. If growth slows further, the premium multiple could compress – the central risk at this valuation.
The Hold label reflects StreetBriefs’ quantitative scoring model (Quality, Growth, Opportunity) – a data-driven signal for further research, not a personalized recommendation to transact. Medical device stocks can move sharply on procedure data, hospital capital budgets and regulatory decisions.
Financial Metrics Summary
| Metric | Value |
|---|---|
| Price & Valuation | |
| Current Price | $401.24 |
| 2-Year Low | $337.50 |
| 2-Year High | $595.55 |
| Market Cap | $143.76B |
| P/E Ratio | 46.12 |
| EV / Revenue | 12.56 |
| Our Scores | |
| Quality Score | 95 / 100 |
| Growth Score | 64 / 100 |
| Opportunity Score | 27 / 100 |
| Profitability | |
| Earnings Per Share | $8.70 |
| Return on Assets | 10.5% |
| Return on Equity | 17.4% |
| Net Profit Margin | 28.4% |
| Gross Margin | 66.7% |
| Operating Margin | 33.6% |
| Growth | |
| Revenue Growth (5Y CAGR) | 17.4% |
| Revenue Growth (TTM) | 18.5% |
| Earnings Growth (TTM) | 26.5% |
| Balance Sheet | |
| Current Ratio | 4.96 |
| Quick Ratio | 3.64 |
| Income & Dividends | |
| Payout Ratio | 0.0% |
Data as of October 02, 2026
Our Three-Pillar Assessment
| Quality |
95/100 |
| Growth |
64/100 |
| Opportunity |
27/100 |
Quality measures business fundamentals: profitability, cash flow discipline, and balance sheet strength.
Growth captures revenue momentum, gross margin scalability, and the Rule of 40 efficiency test.
Opportunity signals entry timing: current valuation versus history and price position in the 2-year range.
Current price: $401.24 trading 33% below its 2-year high of $595.55.
Keep researching ISRG
Follow ISRG’s scores in Qubits Finance
The Quality, Growth and Opportunity scores above come from the same model that powers the Qubits Finance screener. Compare ISRG with its peers, keep it on a watchlist, and see when its scores change. There, the model’s Buy, Hold and Sell signals read Positive, Neutral and Caution.
See ISRG in the screener →What Qubits Finance offers
The screener is on the free plan; accounts are approved by a person during the private beta. Research tools and information only: Qubits Finance does not place trades or make personal recommendations. Want a stock we have not covered? Request an analysis.
This analysis is done using financial data from Yahoo Finance.
Always conduct your own due diligence and consult a qualified financial advisor before making investment decisions.